* Bionano Genomics Inc is expected to show a rise in quarterly revenue when it reports results on March 5 for the period ending December 31 2023
* The San Diego California-based company is expected to report a 28.8% increase in revenue to $10.585 million from $8.22 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.The company's guidance on January 8 2024, for the period ended December 31, was for revenue between $10.40 million and $10.70 million.
* LSEG's mean analyst estimate for Bionano Genomics Inc is for a loss of 87 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Bionano Genomics Inc is $7.00, above its last closing price of $1.25.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2023 -0.92 -0.97 -1.00 Missed -3.1
Jun. 30 2023 -1.00 -1.03 -1.24 Missed -20
Mar. 31 2023 -1.10 -1.10 -1.20 Missed -9.1
Dec. 31 2022 -1.14 -1.10 -1.30 Missed -18.2
Sep. -1.18 -1.15 -1.10 Beat 4.3
30 2022
Jun. 30 2022 -1.03 -0.91 -1.10 Missed -20.4
Mar. 31 2022 -0.87 -0.75 -1.10 Missed -46.7
Dec. 31 2021 -0.64 -0.65 -0.80 Missed -23.6
This summary was machine generated March 1 at 21:25 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments